1-5 of 5
Jan C. Buckner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

Evanthia Galanis, S. Keith Anderson, Jackie M. Lafky, Joon H. Uhm, Caterina Giannini, Shaji K. Kumar, Teresa K. Kimlinger, Donald W. Northfelt, Patrick J. Flynn, Kurt A. Jaeckle, Timothy J. Kaufmann, Jan C. Buckner
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (17): 4816–4823.
https://doi.org/10.1158/1078-0432.CCR-13-0708
Published: 02 September 2013
View articletitled, Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Open the PDF for Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial in another window
Includes: Supplementary data
Journal Articles

SSBP2 Variants Are Associated with Survival in Glioblastoma Patients

Yuanyuan Xiao, Paul A. Decker, Terri Rice, Lucie S. McCoy, Ivan Smirnov, Joseph S. Patoka, Helen M. Hansen, Joe L. Wiemels, Tarik Tihan, Michael D. Prados, Susan M. Chang, Mitchel S. Berger, Matthew L. Kosel, Brooke L. Fridley, Daniel H. Lachance, Brian Patrick O'Neill, Jan C. Buckner, Reid C. Thompson, Louis Burt Nabors, Jeffrey J. Olson, Steve Brem, Melissa H. Madden, James E. Browning, John K. Wiencke, Kathleen M. Egan, Robert B. Jenkins, Margaret R. Wrensch
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (11): 3154–3162.
https://doi.org/10.1158/1078-0432.CCR-11-2778
Published: 31 May 2012
View articletitled, SSBP2 Variants Are Associated with Survival in Glioblastoma Patients
Open the PDF for SSBP2 Variants Are Associated with Survival in Glioblastoma Patients in another window
Includes: Supplementary data
Journal Articles

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Jann N. Sarkaria, Eva Galanis, Wenting Wu, Allan B. Dietz, Timothy J. Kaufmann, Michael P. Gustafson, Paul D. Brown, Joon H. Uhm, Ravi D. Rao, Laurence Doyle, Caterina Giannini, Kurt A. Jaeckle, Jan C. Buckner
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (22): 5573–5580.
https://doi.org/10.1158/1078-0432.CCR-10-1453
Published: 14 November 2010
View articletitled, Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
Open the PDF for Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Manuel Hidalgo, Jan C. Buckner, Charles Erlichman, Marilyn S. Pollack, Joseph P. Boni, Gary Dukart, Bonnie Marshall, Lisa Speicher, Laurence Moore, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (19): 5755–5763.
https://doi.org/10.1158/1078-0432.CCR-06-0118
Published: 04 October 2006
View articletitled, A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
Open the PDF for A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer in another window
Journal Articles

Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer

Patrick A. Burch, Jami K. Breen, Jan C. Buckner, Dennis A. Gastineau, Judith A. Kaur, Reiner L. Laus, Douglas J. Padley, Madhusudan V. Peshwa, Henry C. Pitot, Ronald L. Richardson, Bouwien J. Smits, Pitsata Sopapan, George Strang, Frank H. Valone, Stanimir Vuk-Pavlović
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (6): 2175–2182.
Published: 01 June 2000
View articletitled, Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer
Open the PDF for Priming Tissue-specific Cellular Immunity in a Phase I Trial of Autologous Dendritic Cells for Prostate Cancer in another window